The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.
 
Brian Wolpin
Consulting or Advisory Role - Agenus; BeiGene; Bristol Myers Squibb Foundation; EcoR1 Capital; Harbinger Health; Immuneering; Ipsen; Mirati Therapeutics; Revolution Medicines; Takeda; Tango Therapeutics; Third Rock Ventures
Research Funding - Agios; Amgen (Inst); AstraZeneca (Inst); Harbinger Health (Inst); Lilly (Inst); Novartis (Inst); Revolution Medicines (Inst)
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bridgebio; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; Phanes Therapeutics; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Andrew Hendifar
Consulting or Advisory Role - Alcresta Therapeutics; Amgen; Curium Pharma; Exelixis; Faraday Pharmaceuticals; Ipsen; Merck; Novartis; Pancreatic Cancer Action Network; Pfizer; Regeneron; Valar Labs
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - Halozyme
Other Relationship - Rayzebio
 
Mitesh Borad
Stock and Other Ownership Interests - Abeona Therapeutics; ADC Therapeutics; Assertio Therapeutics; Homology Medicines
Consulting or Advisory Role - Amplia Therapeutics; Breakthru Bio; Cardinal Health; Cogent Biosciences; Delcath Systems; Eisai (Inst); Elevar Therapeutics (Inst); George Clincal; Guardant Health; Jazz Pharmaceuticals; Karkinos Healthcare; Khora Therapeutics; Merck; Moderna Therapeutics; Processa Pharmaceuticals; RayzeBio; Reignite Therapeutics; Revolution Medicines; Roche Molecular Diagnostics; SERVIER; Sirtex Medical; Vionix
Research Funding - Adaptimmune (Inst); Alentis Therapeutics (Inst); Arvinas (Inst); AstraZeneca (Inst); Biond Biologics (Inst); BioNTech SE (Inst); Compass Therapeutics (Inst); Elevar Therapeutics (Inst); Elevation Oncology (Inst); Incyte (Inst); Innovent Biologics (Inst); Kinnate Biopharma (Inst); MediLink Therapeutics (Inst); Merck Serono (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Qurient (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Seagen (Inst); Tango Therapeutics (Inst); ZielBio (Inst)
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Incyte; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Revolution Medicines; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); BeOne (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Johnson & Johnson/Janssen; Merck Serono; Pierre Fabre; Takeda Science Foundation
 
Shubham Pant
Stock and Other Ownership Interests - Oncomed LLC; Teleprian
Consulting or Advisory Role - Alligator Bioscience; Arcus Biosciences; AskGene Pharma; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; BPGbio; Daiichi Sankyo; EMD Serono; Immuneering; Ipsen; Janssen; Jazz Pharmaceuticals; Merck; Nihon Medi-Physics; Novartis; Pfizer; Revolution Medicines; US WorldMeds
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); BMS GmbH & Co. KG (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Pascal Hammel
Honoraria - Astellas Pharma; Pfizer; SERVIER
Consulting or Advisory Role - AstraZeneca (Inst); Revolution Medicines; Servier/Pfizer; VECT-HORUS
Speakers' Bureau - AstraZeneca; Mylan; SERVIER
Research Funding - AstraZeneca (Inst); ERYTECH Pharma (Inst)
Travel, Accommodations, Expenses - Pfizer; Revolution Medicines; SERVIER
 
Chiara Cremolini
Honoraria - Amgen; Bayer; GlaxoSmithKline; Medscape; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bayer; Bicara Therapeutics; GlaxoSmithKline; MSD; Nordic Bioscience; Pierre Fabre; Revolution Medicines; Roche; Rottapharm Biotech; Takeda
Research Funding - Amgen; Bayer (Inst); Merck (Inst); Nordic Bioscience; Pierre Fabre; Roche (Inst); SERVIER; Takeda
 
Gulam Manji
Stock and Other Ownership Interests - EnGeneIC
Honoraria - Celgene; Exelixis; Roche/Genentech
Consulting or Advisory Role - Cend Therapeutics; EnGeneIC; Exelixis; Ipsen; Pfizer; Revolution Medicines; Roche/Genentech
Research Funding - Arcus Biosciences; BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; DAVA Oncology; Exelixis; Revolution Medicines; Roche/Genentech
 
Paul Oberstein
Consulting or Advisory Role - Boehringer Ingelheim; Ipsen; Janssen Oncology; Jazz Pharmaceuticals; Loxo/Lilly; Revolution Medicines
Speakers' Bureau - Ipsen; Jazz Pharmaceuticals
Research Funding - Amal Therapeutics (Inst); Arcus Biosciences (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst)
Expert Testimony - Merck
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Abbvie; Blueprint Medicines; EcoR1 Capital; Fortvita; Guidepoint Global; Kestrel Therapeutics; KeyQuest Health; KeyQuest Health; Lilly; Quanta Therapeutics; Revolution Medicines; SOTIO
Research Funding - 280 BIO (Inst); ABM (Inst); Bayer (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); EcoR1 Capital; GlaxoSmithKline (Inst); Guidepoint Inc; Incyte (Inst); Jacobio (Inst); Kumquat Biosciences (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tango Therapeutics (Inst); Tolero Pharmaceuticals (Inst); Yingli Pharma (Inst)
 
Christoph Springfeld
Consulting or Advisory Role - Bayer; Eisai; MSD; Revolution Medicines; Roche; SERVIER; Taiho Oncology
Travel, Accommodations, Expenses - Servier
 
Nilofer Azad
Stock and Other Ownership Interests - Cage Pharma; Irazu; Tempus
Consulting or Advisory Role - Agenus; Astellas Pharma; AstraZeneca; BeiGene; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Taiho Pharmaceutical; Tempus
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Revolution Medicines (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Makoto Ueno
Honoraria - Amgen; Asca; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; Revolution Medicines; SERVIER; Taiho Pharmaceutical; Takeda; Viatris
Consulting or Advisory Role - Boehringer Ingelheim; Novocure
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Ono Pharmaceutical (Inst); Revolution Medicines (Inst); Taiho Pharmaceutical (Inst)
 
Stephen Chui
Employment - Genentech/Roche; Revolution Medicines Inc.
Stock and Other Ownership Interests - Genentech/Roche; Revolution Medicines Inc.
Honoraria - Revolution Medicines
Consulting or Advisory Role - Genentech/Roche; Revolution Medicines
Research Funding - Genentech/Roche; Revolution Medicines
Patents, Royalties, Other Intellectual Property - I am named on several patents for Genentech and Roche products, in my capacity as an employee of Genentech and Roche
Travel, Accommodations, Expenses - Genentech/Roche; Revolution Medicines
Other Relationship - Genentech/Roche; Revolution Medicines
 
Ying Zhang
Employment - Merck (I); Revolution Medicines
Stock and Other Ownership Interests - Merck (I); Revolution Medicines
 
Hina Patel
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Yeonju Lee
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Zeena Salman
Employment - Revolution Medicines
Stock and Other Ownership Interests - Revolution Medicines
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); Agenus; Alligator Bioscience; Arcus Biosciences; Astellas Pharma; AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; BMSi; Genentech/Roche (I); Immuneering; J-Pharma (I); Merck; Merck Serono (I); Novartis; Pfizer; Regeneron; Revolution Medicines; SERVIER (I); Tango Therapeutics; Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Amgen (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Revolution Medicines (Inst); Tango Therapeutics (Inst)
Travel, Accommodations, Expenses - BioNTech SE